Antineoplastic agents associated with the development of drug-induced pancreatitis

The frequency of drug-induced pancreatitis (LIP) is from 2 to 5% of all cases of acute pancreatitis (OP), but it is much more common in risk groups – among children and HIV-infected patients. The use of a number of drugs (drugs) is associated with the development of lipids, among them a special place is occupied by antitumor drugs due to the great medical and social significance of oncological diseases and the appearance in recent years of a large number of new antitumor drugs. The purpose of this review was to review the literature data on antitumor drugs, the use of which is associated with the development of lipids. LI OP developed in 1.8% of patients treated with nivolumab or pembroluzumab. In total, in 14 phase 1-3 studies on the efficacy and safety of ipilimumab, the development of OP was reported in less than 1% of the subjects. Therapy with molecular-targeted targeted drugs, such as tyrosine kinase inhibitors (TKI) or other representatives of the kinase inhibitor class, is also associated with the development of OP. The HP database of the World Health Organization (WHO, World Health Organization Adverse Drug Reaction database) contains reports of individual clinical cases of OP development during treatment with proteosome inhibitors and antibody-drug conjugates. It is known that the following antitumor drugs are also associated with the development of pancreatitis: 6-mercaptopurine, L-asparaginase, tamoxifen, cisplatin, cytarabine, ifosfamide, paclitaxel, docetaxel, oxaliplatin, capecitabine, periwinkle alkaloids, cytosine, cisplatin, interferon alpha-2b, doxorubicin, tamoxifen, gefitinib, vinorelbine, levamizole, methotrexate, 5-fluorouracil, capecitabine, trans-retinoic acid.